This is consistent with the recent finding of the development of AML and T-ALL in a similar FLT3/ITD and DNMT3a-KO double-mutant mouse model.[36] Interestingly, we also found that Dnmt3a dosage significantly impacts survival and the spectrum of neoplasms developing in Flt3ITD/+ mice. This evidence concerns the gene FLT3 and acute lymphoblastic leukemia.